Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.
Graph Therapeutics, a next-generation techbio company developing precision medicines
for inflammatory and immune-mediated diseases, has secured a new $5 million
investment led by Daphni, the Paris-based venture capital firm. Daphni joins
Graph's existing investor syndicate, which includes SquareOne, Merantix
Capital, and NAVEC Investment Management. The company has also secured
The team behind Exscientia's $60M Allcyte acquisition just raised $5M from Daphni to build their own drugs — TFN
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
Bionyra brings in $165M for next-generation immune drugs
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
A Cambridge PhD discovery raised £1.5M led by SCVC to fix gene therapy's costly flaw — TFN
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio
Syntax Bio Announces Expanded Series A and Leadership Appointments
The team behind Allcyte, acquired by Exscientia in a $60M deal, has raised $5M from Daphni to build its own drugs. The startup…
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic
Former Amazon and Meta researchers launch Graphon AI with $8.3M seed round. The startup builds a relational data layer that sits…
Graphon reels in $8.3M for its persistent relational memory platform - SiliconANGLE
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond…
